Industry view on the relative importance of “clonality” of biopharmaceutical-producing cell lines

Biologicals - Tập 44 - Trang 117-122 - 2016
Christopher Frye1, Rohini Deshpande2, Scott Estes3, Kathy Francissen4, John Joly4, Anthony Lubiniecki5, Trent Munro2, Reb Russell6, Tongtong Wang1, Karin Anderson7
1Eli Lilly & Company, Indianapolis, IN 46285, United States
2Amgen Inc, Thousand Oaks, CA, United States
3Biogen Inc, Cambridge, MA, United States
4Genentech, Inc., South San Francisco, CA, United States
5Janssen R&D LLC, Malvern, PA, United States
6Bristol Myers Squibb, Pennington, NJ, United States
7Pfizer Inc, Andover, MA, United States

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Biologicals

Tập 44

117-122

Thông tin tác giả